Free tool
FAERS Monitor: Procardia Xl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019684 or its brand name (Procardia Xl, Nifedipine). Reports on generic versions are filed under their own applications.
Reports
47,621
Serious
36,714
77% of reports
Hospitalization
19,502
Death reported
5,300
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,641
- dyspnoea2,507
- fatigue2,421
- diarrhoea2,388
- nausea2,320
- off label use2,171
- headache2,101
- dizziness1,846
- hypertension1,835
- pain1,739
- death1,565
- asthenia1,539
- pneumonia1,538
- acute kidney injury1,514
- hypotension1,493
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 951 |
| 2005 | 1,016 |
| 2006 | 1,021 |
| 2007 | 777 |
| 2008 | 937 |
| 2009 | 1,038 |
| 2010 | 1,287 |
| 2011 | 1,445 |
| 2012 | 1,576 |
| 2013 | 1,306 |
| 2014 | 1,727 |
| 2015 | 2,093 |
| 2016 | 2,537 |
| 2017 | 2,782 |
| 2018 | 3,241 |
| 2019 | 3,663 |
| 2020 | 3,286 |
| 2021 | 3,017 |
| 2022 | 2,926 |
| 2023 | 2,986 |
| 2024 | 3,075 |
| 2025 | 2,834 |
| 2026 | 2,094 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,006,538 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 1,514 | 4.4 | 4.2 | 3,968 |
| hypertensionSignal | 1,835 | 3.9 | 3.7 | 3,876 |
| hypotensionSignal | 1,493 | 3.3 | 3.1 | 2,402 |
| pneumoniaSignal | 1,538 | 2.1 | 2.0 | 899 |
| dyspnoea | 2,507 | 2.0 | 1.9 | 1,206 |
| asthenia | 1,539 | 1.8 | 1.7 | 566 |
| dizziness | 1,846 | 1.6 | 1.6 | 466 |
| diarrhoea | 2,388 | 1.6 | 1.6 | 607 |
| headache | 2,101 | 1.5 | 1.4 | 337 |
| fatigue | 2,421 | 1.4 | 1.3 | 255 |
| nausea | 2,320 | 1.3 | 1.2 | 162 |
| pain | 1,739 | 1.3 | 1.2 | 90 |
| off label use | 2,171 | 1.1 | 1.1 | 19 |
| drug ineffective | 2,641 | 0.9 | 0.9 | 42 |
| death | 1,565 | 0.8 | 0.8 | 79 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.